ImmuneOncia Therapeutics, Yuhan's anticancer drug research and development (R&D) subsidiary, said it held a board meeting on the 6th and decided to conduct a rights offering worth 120 billion won.
The purpose is to raise operating funds, and it will proceed with a general public offering of forfeited shares after allocation to shareholders. Subscriptions will take place over two days from Apr. 22 to 23.
The company will issue 16,832,000 new common shares through this rights offering. This is equivalent to 23% of the total number of shares outstanding before the capital increase (74,155,069 shares). The issue price of the new shares is 7,130 won per common share, and the issue price will be finalized on Apr. 17. The number of new shares allocated per one share is 0.2269289333. The new share issue price of 7,130 won is a 25% discount to the reference price (10,040 won).
The record date for the allocation of new shares is Mar. 17, and payment for the rights offering is due on Apr. 30. The new shares are scheduled to be listed on May 18.
Meanwhile, ImmuneOncia Therapeutics' annual revenue for 2025 was provisionally tallied at about 111.21 million won, down 83% from a year earlier. Over the same period, the operating loss was 28.3 billion won, with the deficit widening by 15.7 billion won. The net loss was about 27.7 billion won. The company said the operating loss increased due to higher research and development expenses.